Skip to main content
logo
Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
84.59
+2.03 (2.46%)
May 12, 2026, 1:08 PM EDT - Market open

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Jan '16 Jan '15 Dec '13 Dec '12
United States Revenue
17.23B17.13B16.32B
United States Revenue Growth
0.62%4.92%5.64%
Germany Revenue
-2.76B2.54B
Germany Revenue Growth
-8.67%8.27%
China Revenue
-1.91B2.11B
China Revenue Growth
--9.75%-6.21%
India Revenue
-1.87B1.82B
India Revenue Growth
-2.97%3.83%
Switzerland Revenue
-1.87B1.75B
Switzerland Revenue Growth
-7.10%6.65%
Japan Revenue
-1.48B1.44B
Japan Revenue Growth
-2.36%-4.76%
Netherlands Revenue
--1.12B
Netherlands Revenue Growth
--4.66%
United Kingdom Revenue
-1.34B1.19B
United Kingdom Revenue Growth
-13.08%19.58%
All Other Countries Revenue
-15.98B14.79B
All Other Countries Revenue Growth
-8.07%4.98%
Total International Revenue
27.90B27.20B25.63B
Total International Revenue Growth
2.57%6.15%3.93%
Revenue (Other)
--1.34B-1.19B
Revenue (Total)
45.13B44.33B41.95B
Revenue (Total) Growth
1.82%5.67%4.59%

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Jan '16 Jan '15 Dec '13 Dec '12
Established Pharmaceutical Products Revenue
5.70B5.54B5.19B
Established Pharmaceutical Products Revenue Growth
3.00%6.59%2.53%
Nutritionals Revenue
8.32B8.45B8.41B
Nutritionals Revenue Growth
-1.53%0.45%3.18%
Diagnostics Revenue
9.06B8.94B9.34B
Diagnostics Revenue Growth
1.41%-4.32%-6.48%
Medical Devices Revenue
22.03B21.39B18.99B
Medical Devices Revenue Growth
3.01%12.65%12.43%
Other Segment Revenue
16.00M17.00M16.00M
Other Segment Revenue Growth
-5.88%6.25%14.29%
Revenue (Total)
45.13B44.33B41.95B
Revenue (Total) Growth
1.82%5.67%4.59%

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Jan '16 Jan '15 Dec '13 Dec '12
Established Pharmaceutical Products Operating Earnings
1.36B1.29B1.23B
Established Pharmaceutical Products Operating Earnings Growth
5.19%4.62%2.24%
Nutritionals Operating Earnings
1.48B1.56B1.51B
Nutritionals Operating Earnings Growth
-5.33%3.52%12.90%
Diagnostics Operating Earnings
1.72B1.74B2.07B
Diagnostics Operating Earnings Growth
-1.38%-16.06%-14.80%
Medical Devices Operating Earnings
7.50B7.21B6.15B
Medical Devices Operating Earnings Growth
3.94%17.21%15.96%
Operating Income (Other)
-4.34B-3.75B-4.14B
Operating Income (Total)
7.71B8.05B6.83B
Operating Income (Total) Growth
-4.32%17.99%5.36%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Jan '16 Jan '15 Dec '13 Dec '12
Organic Sales Growth
5.50%9.60%
Updated Apr 29, 2026. Data Source: Fiscal.ai.